



## Jagsonpal Pharmaceuticals announces FY23 Results

### Reports strong operational and financial performance

Board recommends dividend of ₹ 5 per share (100%)

Revenues grew by 8.8% to ₹ 237 Crores

Operating EBITDA grew by 80.7% to ₹ 43 Crores, EBITDA margin at 18.3%

PAT grew by 41.7% to ₹ 27 Crores

**Gurugram, May 23, 2023: Jagsonpal Pharmaceuticals Limited** (BSE: 507789, NSE: JAGSNPHARM) today announced the financial results for the year ended March 31<sup>st</sup>, 2023

A detailed presentation on the performance is included as part of this press release

₹ in lakhs	Q4 FY23	Q4 FY22	FY23	FY22
Revenues	5,545	5,123	23,671	21,758
Operating EBITDA	936	78	4,337	2,399
EBITDA Margin	16.9%	1.5%	18.3%	11.5%
PAT	560	32	2,672	1,885

\* Before ESOP accounting and one-time expenses

Commenting on the Company's performance, Mr. Manish Gupta, Managing Director stated "FY23 has been an extremely important and transformational year for us at Jagsonpal. The year saw Infinity Holdings becoming the largest shareholder in the company and the consequent changes across the governance and operational framework.

I am pleased to report strong performance across all operating and financial matrices in a year of significant transition. While our revenues grew at 8.8%, the improvement in the quality of business aided expansion of operating margins by 680 bps, driving significant improvement in operational profits and balance sheet.

The performance is reflective of the strong brand equity of Jagsonpal. Our key brands are on growth track with Divatrone (our dydrogesterone brand) emerging as our largest brand within 18 months of launch.

With cash reserves in excess of ₹ 115 crores, we have put in place a clear roadmap for accelerating growth even as we evaluate opportunities for strategic use of our cash surplus."

## **ABOUT JAGSONPAL PHARMACEUTICALS LIMITED**

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of 40+ years of catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynecology and Orthopedic segments. Over the years, the Company has successfully built multiple brands that today hold market-leading position in respective segments. It has created a niche for itself in these value-accretive segments with 17 brands amongst Top 5 brands in the molecule category. It has an extensive pan-India presence through its strong sales team of 900+ individuals.

Infinity Holdings acquired a majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange Limited (BSE).

For more information, please visit: [www.jagsonpal.com](http://www.jagsonpal.com)

Mr. S.V. Subha Rao

Chief Financial Officer

Contact: [cs@jagsonpal.com](mailto:cs@jagsonpal.com), +91 124 4406710

Jagsonpal Pharmaceuticals Limited

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Corporate Office: Nimai Tower, 3<sup>rd</sup> floor, Udyog Vihar, Gurugram – 122015